IGC Pharma, Inc. (IGC)

Revenue by Segment

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Life Sciences Segment	1.27M	1.35M	798.00K	359.00K	723.00K
Infrastructure Segment	-	-	113.00K	38.00K	175.00K
Total	1.27M	1.35M	911.00K	397.00K	898.00K

Revenue by Geography

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
United States of America	1.27M	1.18M	777.00K	329.00K	723.00K
Colombia	2.00K	2.00K	21.00K	-	-
India	-	164.00K	113.00K	68.00K	175.00K
Total	1.27M	1.35M	911.00K	397.00K	898.00K

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 7, 2026

Data Sources Report a data error